Description Natural Resource Partners L.P., through its subsidiaries, owns, manages, and leases a portfolio of mineral properties in the United States. It operates through two segments, Mineral Rights and Soda Ash. The company owns interests in coal, soda ash, trona, and other natural resources. Its coal reserves are primarily located in Appalachia, the Illinois Basin, and the Northern Powder River Basin in the United States; industrial minerals and aggregates properties are located in the United States; oil and gas properties located in Louisiana; timber assets located in West Virginia; and trona ore mining operation and soda ash refinery are located in the Green River Basin, Wyoming. The company leases a portion of its reserves in exchange for royalty payments; and owns and leases transportation and processing infrastructure related to coal properties. NRP (GP) LP serves as the general partner of the company. Natural Resource Partners L.P. was incorporated in 2002 and is headquartered in Houston, Texas.
Natural Resource Partners L.P. (NRP)- NYSE - Nasdaq Real Time Price. $46.39+3.06 (+7.06%) As of 01:48PM EDT. Market open.
I also like ERO Copper. Note the Copper plays are short trades for me until I feel the corrective phase this month is clearly over. So I'll play the recent range, buy daily lows sometimes, sell daily highs sometimes. Gold/Silver miners I'm not putting in new money but ... stuff is getting super cheap something to be aware of if Gold/Silver bounces.
Thank you Nine I be sitting on top Copper Mountain staring down at everyone. Van Primo water... that's not water from Mexico is it....
ROLLING THE DICE- HC Wainwright has initiated coverage of DICE Therapeutics (NASDAQ:DICE) with a buy rating lauding the company's DELSCAPE technology platform aimed at creating new therapies against "difficult to target protein-protein interactions (PPIs), using small, targeted DNA-enabling libraries (DELs)." Thefirm has a $40 price target (~151% upside based on Friday's close). Analyst Emily Bodnar said that DELSCAPE can "identify selective binders by producing small, targeted DELs which has led to hundreds to tens of thousands of hits against difficult PPI targets." The company's lead candidate DC-806, a pill that targets IL-17, is being eyed for psoriasis. It is currently in phase 1. Bodnar conceded that although there are several IL-17-targeted biologics for psoriasis and related indications, there is only one approved that is a pill, Amgen's (AMGN) Otezla (apremilast). She noted that though Otezla has a PASI-75 score (efficacy) of only ~30%, the drug has more than $2B in annual sales. A full data readout from the phase 1 trial is expected this quarter, and if it is positive, the stock could see significant upside, Bodnar wrote. This came out July 18<----- The full data read out..... not yet.